ArticleCurrent research in microbial sciences2025
Gut microbial communities in chronic rhinosinusitis patients in response to 1,8-Cineol treatment.
Article in Current research in microbial sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bacterial and fungal communities and network dynamics in Otitis media patients upon 1,8-Cineol treatment.NPJ systems biology and applications · 2026Article
- Chronic Rhinosinusitis at the Interface of Type 2 Inflammation, Epithelial Barrier Dysfunction, and Microbiome Dysbiosis.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic rhinosinusitis (CRS) is a widespread inflammatory disease of the paranasal sinuses and the standard treatment includes surgery and the administration of corticosteroids or antibiotics. Antibiotics are well known to influence the microbial composition of the gut, including a reduced bacterial diversity and an increased antibiotic resistance. This underlines the need for alternative treatment approaches, especially regarding vulnerable patients such as children. Therefore, we evaluated the intestinal microbiota of CRS patients regarding plant-based anti-inflammatory monoterpene 1,8-Cineol, which is administered as the clinically approved drug Soledum® for the therapy of different inflammatory airway diseases including CRS. Methods: Microbiome analysis from stool samples was performed from 31 CRS patients before and after 1,8-Cineol administration using 16S rRNA gene next generation sequencing using dissimilarity-based and taxonomic approaches. Results: Data revealed elevated abundances of specific taxa including Conclusion: Our data recommend 1,8-Cineol as a valuable addition to the current standard treatment of inflammatory diseases, without running the risk of profound changes of the gut microbial community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.